Literature DB >> 32464279

Mitochondrial migraine; a prevalence, impact and treatment efficacy cohort study.

Laurie H Tiehuis1, Saskia Koene2, Christiaan G J Saris3, Mirian C H Janssen4.   

Abstract

Mitochondrial respiratory chain dysfunction may be predisposing for the development of migraine, reflected in high migraine prevalence in patients with mitochondrial disease. Prevalence and impact of migraine in patients with proven mitochondrial disease and the current treatment efficacy were studied using online questionnaires. Patients were selected at the Internal Medicine Department. Headache was reported by 34 (55%) out of 62 patients. Migraine-criteria were met by 85% of them. Efficacy of migraine treatment was achieved in 4 patients. Given the high prevalence of migraine and current treatment insufficiency, migraine is a major threat of quality of life patients with mitochondrial disease.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Headache; MELAS; MIDD; Migraine; Mitochondrial disease; m.3243A>G mutation

Year:  2020        PMID: 32464279     DOI: 10.1016/j.mito.2020.05.004

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  8 in total

1.  Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review.

Authors:  Guido Primiano; Eleonora Rollo; Marina Romozzi; Paolo Calabresi; Serenella Servidei; Catello Vollono
Journal:  Neurol Sci       Date:  2022-09-13       Impact factor: 3.830

Review 2.  Brain Energy Deficit as a Source of Oxidative Stress in Migraine: A Molecular Basis for Migraine Susceptibility.

Authors:  Jonathan M Borkum
Journal:  Neurochem Res       Date:  2021-04-30       Impact factor: 3.996

Review 3.  The non-syndromic clinical spectrums of mtDNA 3243A>G mutation.

Authors:  Xiya Shen; Ailian Du
Journal:  Neurosciences (Riyadh)       Date:  2021-04       Impact factor: 0.906

4.  Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge.

Authors:  Frederick G Freitag
Journal:  Front Pain Res (Lausanne)       Date:  2021-08-09

Review 5.  Could Experimental Inflammation Provide Better Understanding of Migraines?

Authors:  Philip Victor Reducha; Lars Edvinsson; Kristian Agmund Haanes
Journal:  Cells       Date:  2022-08-06       Impact factor: 7.666

6.  Case report: Monoclonal CGRP-antibody treatment in a migraine patient with a mutation in the mitochondrial single-strand binding protein (SSBP1).

Authors:  Katharina Kaltseis; Elisabetta Indelicato; Gregor Broessner; Sylvia Boesch
Journal:  Front Neurol       Date:  2022-09-15       Impact factor: 4.086

7.  The relevance of migraine in the clinical spectrum of mitochondrial disorders.

Authors:  Alberto Terrin; Luca Bello; Maria Lucia Valentino; Leonardo Caporali; Gianni Sorarù; Valerio Carelli; Ferdinando Maggioni; Massimo Zeviani; Elena Pegoraro
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

8.  Headache and migraine in mitochondrial disease and its impact on life-results from a cross-sectional, questionnaire-based study.

Authors:  Philipp Burow; Anneke Meyer; Steffen Naegel; Stefan Watzke; Stephan Zierz; Torsten Kraya
Journal:  Acta Neurol Belg       Date:  2021-03-08       Impact factor: 2.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.